Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 15/20 | 0.53 |
| ▸ | SRC | P12931 | 15/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.53 |
| ▸ | BRAF | P15056 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933460 | 0.84 | HCK (0.51) | HCKSRCMAPK14MAPK12BRAF | |
| SCHEMBL23071126 | 0.81 | BRAF (0.52) | HCKSRCMAPK14MAPK12BRAF | |
| SCHEMBL3755095 | 0.81 | BRAF (0.56) | BRAF | |
| SCHEMBL3758499 | 0.81 | HCK (0.62) | HCKSRCMAPK14MAPK12BRAF | |
| SCHEMBL2929800 | 0.78 | HCK (0.49) | HCKSRCMAPK14MAPK12BRAF | |
| SCHEMBL2933845 | 0.78 | HCK (0.65) | HCKSRCMAPK14MAPK12BRAF | |
| Hydrochloric Acid SCHEMBL29396562 | 0.77 | HCK (0.48) | HCKSRCMAPK14MAPK12BRAF | |
| SCHEMBL28697170 | 0.76 | HCK (0.64) | HCKSRCMAPK14MAPK12BRAF | |
| SCHEMBL20382933 | 0.75 | HCK (0.47) | HCKSRCMAPK14MAPK12BRAF | |
| SCHEMBL3759359 | 0.75 | BRAF (0.42) | HCKSRCMAPK14MAPK12BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-8912191-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-12-16 | — | — | US | disclosed |
| EP-2229391-B1 | PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2014-05-01 | — | — | US | disclosed |
| US-8546387-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-09-20 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | HCK 408/4885SRC 80/4885MAPK14 250/4885 |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | HCK 408/4885SRC 80/4885MAPK14 250/4885 |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | HCK 408/4885SRC 80/4885MAPK14 250/4885 |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | HCK 408/4885SRC 80/4885MAPK14 250/4885 |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | HCK 408/4885SRC 80/4885MAPK14 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.